Rebyota Suspension
Product Images NDC 55566-9800

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rebyota (NDC 55566-9800). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ferring Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Rebyota 01)

An instructional illustration showing components related to Rebyota rectal suspension administration: a sealed opaque bag containing thawed Rebyota with a spike port; an administration set with tube spike and pinch clamp; a water-soluble lubricant (not included); and a disposable underpad (not included).*

FDA Label Image

Figure 2 (Rebyota 02)

Illustration labeled as Figure 2 showing a valve mechanism attached to a tube. The valve has an arrow indicating flow direction, depicting a control or check valve function within the tubing system.*

FDA Label Image

Figure 3 (Rebyota 03)

An instructional illustration showing components of the Rebyota 50000000000 CFU/150 mL suspension for rectal administration. It depicts a sealed opaque bag containing thawed Rebyota connected to a spike port, which attaches to an administration tube spike for drug delivery.*

FDA Label Image

Figure 4 And Figure 5 (Rebyota 04)

Illustration showing two patient positioning options: Figure 4 depicts the left-side position where the patient lies on the left side with knee bent and arms resting comfortably. Figure 5 shows the knee-chest position, where the patient kneels, then lowers head and chest forward until the left side of the face rests on the surface with the left arm folded comfortably.*

FDA Label Image

Figure 6 (Rebyota 05)

An instructional diagram showing a rectal applicator tube with a measurement indicating to insert approximately 12 cm (5 inches) into the rectum.*

FDA Label Image

Figure 7 And Figure 8 (Rebyota 06)

Two instructional illustrations showing patient positioning for administration of Rebyota (Donor Human Stool) suspension by rectal route. Figure 7 depicts a patient lying on their left side with the right leg bent forward. Figure 8 shows a patient lying on their right side with the left leg bent forward. Both images include icons indicating no IV drip or certain equipment present.*

FDA Label Image

Figure 9 And Figure 10 (Rebyota 07)

Illustrations showing two alternative patient positions used in the administration process of Rebyota suspension: one with the patient lying on their side with knees slightly bent, and the other with the patient in a knee-chest position. Both images include a clock graphic indicating 'up to 15 min.'*

FDA Label Image

Principal Display Panel (150 mL Bag Carton)

Rebyota 50 billion CFU/150mL fecal microbiota, live-jslm suspension for rectal administration by Ferring Pharmaceuticals. The packaging shows a single-dose carton with storage, thawing, and usage instructions, including details about freezing and refrigeration temperatures. The label also includes the product name, active ingredient, barcode, and manufacturer information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.